New Treatment for Lambert-Eaton Myasthenic Syndrome Approved by FDA!
https://patientworthy.com/wp-content/uploads/2018/11/perspective-175642_1280.png

New Treatment for Lambert-Eaton Myasthenic Syndrome Approved by FDA!

Lambert-Eaton Myasthenic Syndrome (LEMS) is an autoimmune disorder. It's a rare condition characterized by muscle weakness in the limbs. When the muscle weakness includes the respiratory muscles, the disease can…

Continue Reading New Treatment for Lambert-Eaton Myasthenic Syndrome Approved by FDA!
Woman Plans Slams Doctors With Lawsuit After Failing to Tell Her About Her Father’s Huntington’s Disease
witwiccan / Pixabay

Woman Plans Slams Doctors With Lawsuit After Failing to Tell Her About Her Father’s Huntington’s Disease

According to a story from Science Alert, an ugly and unpleasant tale involving the devastating rare genetic illness known as Huntington's disease will culminate in a lawsuit. The outcome of…

Continue Reading Woman Plans Slams Doctors With Lawsuit After Failing to Tell Her About Her Father’s Huntington’s Disease
This Company Will Work With Nonprofit Organizations to Develop New Treatment for Epidermolysis Bullosa
DarkoStojanovic / Pixabay

This Company Will Work With Nonprofit Organizations to Develop New Treatment for Epidermolysis Bullosa

According to a story from PR Newswire, the biopharmaceutical company Constant Pharmaceuticals recently announced that it plans to develop its experimental compound TXA127 as a therapy for epidermolysis bullosa (EB).…

Continue Reading This Company Will Work With Nonprofit Organizations to Develop New Treatment for Epidermolysis Bullosa
Second Ever Cancer Treatment Based on Biomarkers Approved by FDA
Source: Pixabay.com

Second Ever Cancer Treatment Based on Biomarkers Approved by FDA

On November 26, 2018, a new drug was given accelerated approval by the FDA. Not only that, but it was granted orphan drug designation and breakthrough therapy designation. The drug…

Continue Reading Second Ever Cancer Treatment Based on Biomarkers Approved by FDA
Her Rare Condition Revealed his Rare Ability: Amy and Sam’s Service Dog Story
Source: Pixabay.com

Her Rare Condition Revealed his Rare Ability: Amy and Sam’s Service Dog Story

Amy Dahm, who currently lives in Washington, DC, was working as a U.S. diplomat when she was diagnosed with Cushing’s syndrome. After receiving life-saving treatment from the National Institutes of…

Continue Reading Her Rare Condition Revealed his Rare Ability: Amy and Sam’s Service Dog Story
Genome Sequencing Offers Promise for Children with Rare Developmental Delays and Other Genetic Rare Diseases
source: pixabay.com

Genome Sequencing Offers Promise for Children with Rare Developmental Delays and Other Genetic Rare Diseases

  For many families, when their child is born with developmental delays, there may be weeks, months, or even years that go by without a diagnosis. During this time, parents…

Continue Reading Genome Sequencing Offers Promise for Children with Rare Developmental Delays and Other Genetic Rare Diseases
Experimental Treatment for Charcot-Marie-Tooth Disease Gets FDA Fast Track Designation
annca / Pixabay

Experimental Treatment for Charcot-Marie-Tooth Disease Gets FDA Fast Track Designation

According to a story from Digital Journal, the biopharmaceutical company Acceleron Pharma, Inc., recently announced that its investigational drug candidate ACE-083 was granted Fast Track designation from the US Food…

Continue Reading Experimental Treatment for Charcot-Marie-Tooth Disease Gets FDA Fast Track Designation
Enrollment is Complete for Trial of Experimental Multiple Myeloma Treatment
mwooten / Pixabay

Enrollment is Complete for Trial of Experimental Multiple Myeloma Treatment

According to a story from BioPortfolio, Celgene Corporation and bluebird bio, Inc., have recently announced that enrollment for a pivotal Phase 2 study testing an experimental therapy for relapsed/refractory multiple…

Continue Reading Enrollment is Complete for Trial of Experimental Multiple Myeloma Treatment
Clinical Trial Testing Experimental Treatment for Pulmonary Arterial Hypertension Begins
qimono / Pixabay

Clinical Trial Testing Experimental Treatment for Pulmonary Arterial Hypertension Begins

According to a story from globenewswire.com, the biopharmaceutical company PhaseBio Pharmaceuticals has recently announced that the first patient has been dosed in a Phase 2b clinical trial of the company's…

Continue Reading Clinical Trial Testing Experimental Treatment for Pulmonary Arterial Hypertension Begins